UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
This intro examines risk profiles for index vs target date funds, offering a clear take on volatility, diversification, and potential drawdowns.
24,893 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
KeyBanc lowers its price target for On Holding AG to $43, citing tariff exposure that weighs on margins, even as the ...
ConocoPhillips faces a clash between a wave of Buy ratings and a cautious price target, as crude markets rebound and ...
Today’s stock market activity shows SoFi (SOFI) directing attention as investors weigh inflation signals and higher y...
Stocks extend an eight-week gain streak, signaling persistent momentum amid easing volatility. Here’s what traders ar...
SpaceX is lining up what could be the largest IPO in U.S. history, targeting about $75 billion by selling hundreds of...
New data reveals JNK’s 0.40% expense ratio quietly drains returns, especially for long-term holders, even when junk-b...
Bitcoin edged above $65,000 as oil prices slipped, but traders warn that stubborn dollar strength and elevated yields...
Investors dig into a mixed session as Amazon leads gains on Prime Day momentum and AI shopping activity. This guide b...
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
The U.S. reimposes naval blockade amid intensified strikes and Iranian threats, sending oil prices higher and sparkin...
Matrixport’s fear index shows mounting pessimism as Bitcoin whipsaws in a volatile market. While downside risk remain...